NDAOTICSUSPENSION/DROPS
Approved
Dec 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEO-CORT-DOME is a combination otic suspension containing glacial acetic acid, hydrocortisone, and neomycin sulfate for topical ear canal treatment. It addresses otitis externa and related otic inflammatory conditions through anti-inflammatory, antimicrobial, and acidifying properties. This triple-component formulation has been the standard of care in otic therapy for decades.
LOE Approaching
This mature, established product faces LOE with moderate competitive pressure (30%), indicating a defensive commercial posture focused on retention rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
R-Pharm US is hiring 1 role related to this product
Worked on NEO-CORT-DOME at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.